Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy

Rudzińska, Magdalena; Daglioglu, Cenk; Savvateeva, Lyudmila V.; Kaci, Fatma Necmiye; Antoine, Rodolphe; Zamyatnin, Andrey A.

doi:10.2147/dddt.s285852

Cited by 46 publications

(19 citation statements)

References 132 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, cVVC are less adherent but produce a larger amount of proteases, that would help to invade the tissue and lead to inflammation, a major factor contributing to the progression of the disease [ 6 ]. Therefore, targeted treatment strategies could be employed taking into account the mechanisms used by C. albicans to persist in the vaginal mucosa; particularly topical treatments related to protease inhibitors could be an option for complicated cVVC cases [ 29 ]. Nevertheless, more studies are needed to address this issue.…”

Section: Discussionmentioning

confidence: 99%

Vulvovaginal Candida albicans Clinical Isolates’ Resistance to Phagocytosis In-Vitro

Faria-Gonçalves

Oliveira

Gaspar

et al. 2022

Life

View full text Add to dashboard Cite

Previous studies have revealed that Candida albicans isolates involved in chronic vulvovaginal candidosis (cVVC) phenotypically express less virulent traits than clinical isolates involved in sporadic infections. In this study, we aimed to further explore this finding by studying the behaviour of those same clinical isolates in in-vitro models of infection. Eighteen clinical Candida albicans isolates were collected from women suffering sporadic (eight isolates) or chronic infections (ten isolates). Adhesion to HeLa cells (human cervical cancer epithelial cell line) and resistance to phagocytosis by RAW 264.7 cells (murine macrophages cell line) were tested in-vitro. In addition, phenotypic expression of virulence factors related with either adhesion or resistance to phagocytosis was tested in-vitro. Results indicated that yeast isolates involved in sporadic infection adhered in a higher proportion of HeLa cells than those of chronic infections, which was related with their ability to produce biofilm (p < 0.05). The ability to evade phagocytosis was related to an elevated production of proteases (p < 0.05) by chronic isolates, while sporadic isolates’ resistance to phagocytosis was related to a higher hydrophobicity of cell walls (p < 0.05). We conclude that the evasion of macrophage-mediated phagocytosis related to the production of proteases might be an important factor involved in the recurrence of vulvovaginal candidosis infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Vulvovaginal Candida albicans Clinical Isolates’ Resistance to Phagocytosis In-Vitro

Faria-Gonçalves

Oliveira

Gaspar

et al. 2022

Life

View full text Add to dashboard Cite

show abstract

“…L-glutaminase from Aspergillus fumigatus and Penicillium allii is used for the treatment of leukaemia by inhibiting the growth of cancerous cells [214]. Alkaline protease is also used as a digestible in the pharmaceutical industry to treat cystic fibrosis [215,216]. These proteases control the abnormal concentrations of bile salts and pancreatic selections [109].…”

Section: Medical and Pharmaceutical Industrymentioning

confidence: 99%

“…These inhibitors have developed poor efficacy for clinical outcomes. Conventional chemotherapies for cancer treatment are not reliable due to poor diagnosis of cancerous cells at an early stage of cancer [216,250]. However, present challenges include designing protease inhibitors with a formulation of different types of nanoparticles for the treatment of cancers.…”

Section: Np-delivery Systems For Discovery Of Protease Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Fungal Proteases as Emerging Biocatalysts to Meet the Current Challenges and Recent Developments in Biomedical Therapies: An Updated Review

Naeem

Manzoor²,

Abid

et al. 2022

JoF

View full text Add to dashboard Cite

With the increasing world population, demand for industrialization has also increased to fulfill humans’ living standards. Fungi are considered a source of essential constituents to produce the biocatalytic enzymes, including amylases, proteases, lipases, and cellulases that contain broad-spectrum industrial and emerging applications. The present review discussed the origin, nature, mechanism of action, emerging aspects of genetic engineering for designing novel proteases, genome editing of fungal strains through CRISPR technology, present challenges and future recommendations of fungal proteases. The emerging evidence revealed that fungal proteases show a protective role to many environmental exposures and discovered that an imbalance of protease inhibitors and proteases in the epithelial barriers leads to the protection of chronic eosinophilic airway inflammation. Moreover, mitoproteases recently were found to execute intense proteolytic processes that are crucial for mitochondrial integrity and homeostasis function, including mitochondrial biogenesis, protein synthesis, and apoptosis. The emerging evidence revealed that CRISPR/Cas9 technology had been successfully developed in various filamentous fungi and higher fungi for editing of specific genes. In addition to medical importance, fungal proteases are extensively used in different industries such as foods to prepare butter, fruits, juices, and cheese, and to increase their shelf life. It is concluded that hydrolysis of proteins in industries is one of the most significant applications of fungal enzymes that led to massive usage of proteomics.

show abstract

“…As a result, drugs based on these findings always show great deficiency in patients. The combination of drugs targeting different motifs has shown great advantages according to the outcome of clinical trials, which is more than a single plus of them ( Al-Attar and Madihally, 2020 ; Rudzińska et al, 2021 ). Thus, we hypothesized that the KRAS-associated signature gene set may be an ideal target to counterbalance the burden of KRAS mutations.…”

Section: Introductionmentioning

confidence: 99%

A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer

Luo

Song²,

Guan³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: KRAS mutation, one of the most important biological processes in colorectal cancer, leads to poor prognosis in patients. Although studies on KRAS have concentrated for a long time, there are currently no ideal drugs against KRAS mutations.Methods: Different expression analysis and weighted gene coexpression network analysis was conducted to select candidate genes. Log-rank tests and Cox regression picked out the prognostic genes to build a KRAS-related gene prognostic score (KRGPS). A nomogram based on KRGPS was built to predict survival of clinical patients. Comprehensive analysis showed the prognosis, immune microenvironment and response to immune therapy and chemotherapy in KRGPS subgroups.Results: We collected a KRGPS from the set of two genes GJB6 and NTNG1, with low-KRGSP patients having better progression-free survival (PFS). Low KRGPS is correlated with high infiltration of activated NK cells, plasma cells and activated memory CD4 T cells and that these cells benefit more from immune checkpoint inhibitor therapy. However, high KRGPS is associated with high infiltration of activated mast cells, pathways of immune dysregulation and a high ratio of TP53 and KRAS mutations. KRGPS subgroups are also sensitive to chemotherapy differently. A nomogram, established based on the KRGPS and pathological stage, predict 3- and 5-years PFS well.Conclusions: The KRAS-associated score acts as a promising signature to distinguish prognosis, molecular and immune characteristics, and benefits from immune and chemical therapy. These KRAS-associated genes could be promising targets for drug design.

show abstract

Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy

Cited by 46 publications

References 132 publications

Vulvovaginal Candida albicans Clinical Isolates’ Resistance to Phagocytosis In-Vitro

Vulvovaginal Candida albicans Clinical Isolates’ Resistance to Phagocytosis In-Vitro

Fungal Proteases as Emerging Biocatalysts to Meet the Current Challenges and Recent Developments in Biomedical Therapies: An Updated Review

A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer

Contact Info

Product

Resources

About